Our results are in agreement with recent report revealing that pharmacological inhibition of NLRP3 inflammasome with MCC950 or knockout of NLRP3 abrogate both SARS-CoV-2 replication and associated inflammation during infection of human ACE2 mice (84). This evidence concerns the gene NLRP3 and infection.